Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
Sunshine Biopharma (NASDAQ:SBFM) has successfully closed its previously announced registered direct offering, raising approximately $2.46 million through the sale of Common Stock and pre-funded warrants to institutional investors. The offering, priced at $2.07 per share, included 1,188,404 shares of Common Stock or Pre-Funded Warrants.
The Pre-Funded Warrants, priced at $2.06999 with an exercise price of $0.00001, are immediately exercisable. The transaction, which closed on April 3, 2025, was conducted under Nasdaq rules at market price. The company plans to utilize the net proceeds for general corporate purposes and working capital.
Aegis Capital Corp. served as the exclusive placement agent, with legal representation from various firms. The offering was executed through an effective shelf registration statement on Form S-3.
Sunshine Biopharma (NASDAQ:SBFM) ha chiuso con successo l'offerta diretta registrata precedentemente annunciata, raccogliendo circa $2,46 milioni attraverso la vendita di azioni ordinarie e warrant pre-finanziati a investitori istituzionali. L'offerta, fissata a $2,07 per azione, includeva 1.188.404 azioni ordinarie o warrant pre-finanziati.
I warrant pre-finanziati, valutati a $2,06999 con un prezzo di esercizio di $0,00001, sono immediatamente esercitabili. La transazione, che si è conclusa il 3 aprile 2025, è stata condotta secondo le regole di Nasdaq al prezzo di mercato. L'azienda prevede di utilizzare i proventi netti per scopi aziendali generali e capitale circolante.
Aegis Capital Corp. ha svolto il ruolo di agente di collocamento esclusivo, con rappresentanza legale di vari studi. L'offerta è stata eseguita attraverso una dichiarazione di registrazione di shelf efficace sul modulo S-3.
Sunshine Biopharma (NASDAQ:SBFM) ha cerrado con éxito su oferta directa registrada previamente anunciada, recaudando aproximadamente $2.46 millones a través de la venta de acciones ordinarias y warrants prefinanciados a inversores institucionales. La oferta, fijada a $2.07 por acción, incluyó 1,188,404 acciones ordinarias o warrants prefinanciados.
Los warrants prefinanciados, valorados en $2.06999 con un precio de ejercicio de $0.00001, son ejercitables de inmediato. La transacción, que se cerró el 3 de abril de 2025, se llevó a cabo bajo las reglas de Nasdaq al precio de mercado. La empresa planea utilizar los ingresos netos para fines corporativos generales y capital de trabajo.
Aegis Capital Corp. actuó como agente de colocación exclusivo, con representación legal de varias firmas. La oferta se ejecutó a través de una declaración de registro de estante efectiva en el formulario S-3.
Sunshine Biopharma (NASDAQ:SBFM)는 이전에 발표된 등록된 직접 공모를 성공적으로 마감하고, 기관 투자자들에게 보통주 및 미리 자금을 지원받은 워런트를 판매하여 약 $2.46 백만을 모금했습니다. 이 공모는 $2.07 주당으로 가격이 책정되었으며, 1,188,404 주의 보통주 또는 미리 자금을 지원받은 워런트를 포함했습니다.
미리 자금을 지원받은 워런트는 $2.06999로 평가되며, 행사 가격은 $0.00001로 즉시 행사 가능합니다. 이 거래는 2025년 4월 3일에 마감되었으며, 시장 가격으로 Nasdaq 규정에 따라 진행되었습니다. 회사는 순수익을 일반 기업 목적 및 운영 자금으로 사용할 계획입니다.
Aegis Capital Corp.는 독점적인 배치 대행사로 활동했으며, 여러 법률 회사의 법률 대리를 받았습니다. 이 공모는 S-3 양식의 유효한 선반 등록 성명을 통해 실행되었습니다.
Sunshine Biopharma (NASDAQ:SBFM) a réussi à clôturer son offre directe enregistrée précédemment annoncée, levant environ 2,46 millions de dollars grâce à la vente d'actions ordinaires et de bons de souscription préfinancés à des investisseurs institutionnels. L'offre, fixée à 2,07 dollars par action, comprenait 1 188 404 actions ordinaires ou bons de souscription préfinancés.
Les bons de souscription préfinancés, évalués à 2,06999 $, avec un prix d'exercice de 0,00001 $, sont immédiatement exerçables. La transaction, qui a été clôturée le 3 avril 2025, a été réalisée selon les règles de Nasdaq au prix du marché. La société prévoit d'utiliser les produits nets à des fins générales d'entreprise et de fonds de roulement.
Aegis Capital Corp. a agi en tant qu'agent de placement exclusif, avec une représentation légale de divers cabinets. L'offre a été exécutée par le biais d'une déclaration d'enregistrement de shelf efficace sur le formulaire S-3.
Sunshine Biopharma (NASDAQ:SBFM) hat erfolgreich das zuvor angekündigte registrierte Direktangebot abgeschlossen und etwa 2,46 Millionen USD durch den Verkauf von Stammaktien und vorfinanzierten Warrants an institutionelle Investoren gesammelt. Das Angebot, das auf 2,07 USD pro Aktie festgelegt wurde, umfasste 1.188.404 Stammaktien oder vorfinanzierte Warrants.
Die vorfinanzierten Warrants, die zu $2,06999 bewertet wurden und einen Ausübungspreis von $0,00001 haben, sind sofort ausübbar. Die Transaktion, die am 3. April 2025 abgeschlossen wurde, wurde gemäß den Nasdaq-Regeln zum Marktpreis durchgeführt. Das Unternehmen plant, die Nettoerlöse für allgemeine Unternehmenszwecke und Betriebskapital zu verwenden.
Aegis Capital Corp. fungierte als exklusiver Platzierungsagent mit rechtlicher Vertretung durch verschiedene Kanzleien. Das Angebot wurde durch eine wirksame Shelf-Registrierungserklärung auf dem Formular S-3 durchgeführt.
- Successful completion of $2.46 million capital raise
- Institutional investor participation indicates market confidence
- Immediate access to working capital for operations
- Potential dilution of existing shareholders
- Relatively small offering size may indicate investor interest
- Offering priced at market suggests no premium valuation
Insights
Sunshine Biopharma's $2.46 million registered direct offering represents a significant capital raise relative to the company's $5.69 million market capitalization, resulting in substantial dilution for existing shareholders. The offering price of
The company sold 1,188,404 shares (or pre-funded warrants), which constitutes approximately
While the shelf registration and institutional investor participation suggest this was a planned financing rather than a distress sale, the vague designation of proceeds for "general corporate purposes and working capital" provides little insight into strategic initiatives. For small pharmaceutical companies focused on research, regular capital raises are often necessary to fund operations and development programs, but the lack of specificity regarding use of funds makes it difficult to assess the potential return on investment.
This transaction appears primarily aimed at extending the company's operational runway rather than funding a specific strategic initiative. Given the significant dilution and absence of clear growth catalysts identified in the announcement, this financing likely represents a negative development for existing shareholders despite providing necessary working capital.
FORT LAUDERDALE, FL / ACCESS Newswire / April 3, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced the closing of the previously announced registered direct offering with institutional investors of approximately
The offering consisted of the sale of 1,188,404 shares of Common Stock (or Pre-Funded Warrants). The price per Common Share was
The Company received aggregate gross proceeds from the offering of approximately
Aegis Capital Corp. acted as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.
The registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-284142) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on January 15, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Forward-Looking Statements
The foregoing material may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company's product development and business prospects, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
For additional information, please contact
Mr. Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
How much did Sunshine Biopharma (SBFM) raise in their April 2025 offering?
What was the share price for SBFM's April 2025 registered direct offering?
How many shares were sold in SBFM's April 2025 offering?
What will SBFM use the proceeds from the April 2025 offering for?
When did SBFM's registered direct offering close?
